# Myelodysplastic Syndrome--CDA-2 Hematological Improvement National Affirmation Study

> **NCT03335943** · PHASE4 · UNKNOWN · sponsor: **Chinese Society of Hematology** · enrollment: 800 (estimated)

## Conditions studied

- Myelodysplastic Syndrome (MDS)

## Interventions

- **DRUG:** CDA-2 (Cell Differentiation Agent 2)

## Key facts

- **NCT ID:** NCT03335943
- **Lead sponsor:** Chinese Society of Hematology
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-12-01
- **Primary completion:** 2019-12-01
- **Final completion:** 2020-12-01
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2017-11-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03335943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03335943, "Myelodysplastic Syndrome--CDA-2 Hematological Improvement National Affirmation Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03335943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*